Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

120.25 +1.32 (+1.11%)

Streaming Delayed Price Updated: 3:25 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Merck & Co. Reports Better Than Expected Results For First-Quarter 2025 ↗

April 24, 2025

Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments.

Via Talk Markets

Topics Stocks / Equities

Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story ↗

April 24, 2025

US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline.

Via Benzinga

Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens ↗

April 24, 2025

Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million.

Via Stocktwits

Topics Government World Trade

Merck’s (NYSE:MRK) Q1 Sales Beat Estimates

April 24, 2025

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue...

Via StockStory

Topics Artificial Intelligence Earnings Intellectual Property

Earnings Scheduled For April 24, 2025 ↗

April 24, 2025

Via Benzinga

Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit? ↗

April 24, 2025

This is the third quarter of accelerating sales declines amid slow demand in China for Gardasil vaccines.

Via Investor's Business Daily

Topics Earnings Government Stocks

Merck Announces First-Quarter 2025 Financial Results

April 24, 2025

From Merck & Co., Inc.

Via Business Wire

Why Is Summit Therapeutics Stock Soaring On Wednesday? ↗

April 23, 2025

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

Via Benzinga

Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure? ↗

April 23, 2025

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.

Via Benzinga

BioNTech Surges On Summit's Coattails. But Can They Take On Merck? ↗

April 23, 2025

BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.

Via Investor's Business Daily

Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings

April 23, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect.

Via StockStory

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer ↗

April 21, 2025

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Via Benzinga

Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗

April 21, 2025

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

Via Stocktwits

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

April 21, 2025

Via Benzinga

Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income ↗

April 18, 2025

Via Benzinga

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Via Benzinga

Topics ETFs

Where Will Eli Lilly Be in 5 Years? ↗

April 18, 2025

Via The Motley Fool

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

April 17, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Assessing Merck & Co: Insights From 9 Financial Analysts ↗

April 17, 2025

Via Benzinga

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

April 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Price Over Earnings Overview: Merck & Co ↗

April 15, 2025

Via Benzinga

Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery ↗

April 15, 2025

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology.

Via Benzinga

Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump's 90-Day Tariff Pause: Hakeem Jeffries Calls It 'Problematic' ↗

April 15, 2025

Rep. Marjorie Taylor Greene (R-Ga.) disclosed her significant stock purchases made just before and on the day of former President Donald Trump's announcement to pause global tariffs. This announcement...

Via Benzinga

Topics Government World Trade

MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 14, 2025

From The Schall Law Firm

Via Business Wire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

April 14, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

MRK Investors Have the Opportunity to Lead the Merck Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

April 13, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Deadline Soon: Merck & Co (MRK) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

April 11, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Topics Government Stocks World Trade

3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom

April 10, 2025

These robotics companies could find an opportunity if the latest round of tariffs stimulates an increase in U.S. manufacturing capacity.

Via MarketBeat

Topics Government World Trade

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.